Virax Biolabs director reports option holdings

Virax Biolabs Group Ltd director Nelson M. Haight reported his initial beneficial ownership of stock options in the company.

Rhea-AI Filing Summary

Virax Biolabs Group Ltd director Nelson M. Haight reported his initial beneficial ownership of stock options in the company. The holdings include options over 2,000 Ordinary Shares with a $15.40 exercise price expiring on November 17, 2032, granted under the 2023 Equity Incentive Plan.

He also holds options over 10,000 Ordinary Shares with a $6.00 exercise price expiring on April 18, 2033, 10,000 options at $0.68 expiring on April 18, 2034, and 10,000 options at $0.88 expiring on April 8, 2035. Footnotes state these options vest in scheduled halves or thirds on specified future dates, becoming exercisable as they vest.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider HAIGHT NELSON M

Role Director

Type	Security	Shares	Price	Value
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--
holding	Stock Options (right to buy)	--	--	--

Holdings After Transaction: Stock Options (right to buy) — 32,000 contracts (Direct)

Footnotes (4)

1. F1. On November 17, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on November 17 of each of 2023 and 2024. The vested portions of such options will become exercisable upon vesting.
2. F2. On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting.
3. F3. On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.
4. F4. On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

Key Figures

Option exercise price: $15.40 per share Option exercise price: $6.00 per share Option exercise price: $0.68 per share +1 more

4 metrics

Option exercise price $15.40 per share Stock options on 2,000 Ordinary Shares expiring November 17, 2032

Option exercise price $6.00 per share Stock options on 10,000 Ordinary Shares expiring April 18, 2033

Option exercise price $0.68 per share Stock options on 10,000 Ordinary Shares expiring April 18, 2034

Option exercise price $0.88 per share Stock options on 10,000 Ordinary Shares expiring April 8, 2035

Key Terms

Stock Options (right to buy), Ordinary Shares, 2023 Equity Incentive Plan, 2024 Equity Incentive Plan, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: "Stock Options (right to buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

2023 Equity Incentive Plan financial

"granted 2,000 stock options under the Company's 2023 Equity Incentive Plan"

2024 Equity Incentive Plan financial

"granted 10,000 stock options under the Company's 2024 Equity Incentive Plan"

vest in equal thirds financial

"The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Virax Biolabs (VRAX) Form 3 for Nelson M. Haight show?

The Form 3 shows director Nelson M. Haight holds several stock option awards on Virax Biolabs Ordinary Shares, with different exercise prices and expiration dates, granted under the company’s equity incentive plans and vesting over multiple future years as described in the footnotes.

How many Virax Biolabs (VRAX) options at $15.40 does Nelson Haight report?

Nelson M. Haight reports stock options over 2,000 Ordinary Shares with a $15.40 exercise price, expiring on November 17, 2032. These options were granted under the 2023 Equity Incentive Plan and vest in equal halves on November 17 of 2023 and 2024, becoming exercisable upon vesting.

What are the key terms of Nelson Haight’s $6.00 Virax Biolabs (VRAX) options?

He holds stock options over 10,000 Ordinary Shares with a $6.00 exercise price, expiring on April 18, 2033. Footnotes state this award was granted on April 18, 2023 and vests in equal halves on April 18 of 2024 and 2025, with each vested portion becoming exercisable upon vesting.

What low-priced Virax Biolabs (VRAX) options does Nelson Haight disclose on Form 3?

The filing lists stock options over 10,000 Ordinary Shares at a $0.68 exercise price expiring on April 18, 2034 and another 10,000 options at $0.88 expiring on April 8, 2035. These grants vest in equal thirds over three years from their respective grant dates, then become exercisable.

How do Nelson Haight’s Virax Biolabs (VRAX) options vest over time?

Footnotes explain that each grant vests in scheduled installments: one award in halves over two years, and later awards in halves or thirds over two or three years. The vested portions of each option grant become exercisable upon vesting, aligning compensation with multi-year service at the company.

Are Nelson Haight’s Virax Biolabs (VRAX) options held directly or indirectly?

The Form 3 characterizes all reported stock options as direct ownership. Each line item shows ownership coded as “D,” with no nature-of-ownership footnote transferring voting or investment authority to another entity, indicating the options are held directly by Nelson M. Haight himself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 03:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

HAIGHT NELSON M

(Last) (First) (Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE UNITED KINGDOM ML1 5UH

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	11/17/2032	Ordinary Shares	2,000	$15.4	D
Stock Options (right to buy)	(2)	04/18/2033	Ordinary Shares	10,000	$6	D
Stock Options (right to buy)	(3)	04/18/2034	Ordinary Shares	10,000	$0.68	D
Stock Options (right to buy)	(4)	04/08/2035	Ordinary Shares	10,000	$0.88	D

Explanation of Responses:

1. On November 17, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on November 17 of each of 2023 and 2024. The vested portions of such options will become exercisable upon vesting.

2. On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting.

3. On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

	/s/ Nelson Haight	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)